Progress in myasthenia gravis.
作者信息
Havard C W
出版信息
Br Med J. 1977 Oct 15;2(6093):1008-11. doi: 10.1136/bmj.2.6093.1008.
Abstract
摘要
相似文献
1
Progress in myasthenia gravis.重症肌无力的进展
Br Med J. 1977 Oct 15;2(6093):1008-11. doi: 10.1136/bmj.2.6093.1008.
2
Rational therapy of myasthenia gravis.
Semin Neurol. 1990 Mar;10(1):70-82. doi: 10.1055/s-2008-1041256.
3
Acetylcholine receptor antibody in myasthenia gravis.
Acta Neurol Scand. 1989 Nov;80(5):387-9. doi: 10.1111/j.1600-0404.1989.tb03898.x.
4
[Thymus and myasthenia].[胸腺与重症肌无力]
Rev Med Suisse Romande. 1973 Feb;93(2):143-58.
5
Myasthenia gravis (second of two parts).重症肌无力（两部分中的第二部分）
N Engl J Med. 1978 Jan 26;298(4):186-93. doi: 10.1056/NEJM197801262980404.
6
[Myasthenia gravis. Immunosuppressive treatment].[重症肌无力。免疫抑制治疗]
Tidsskr Nor Laegeforen. 1971 Apr 20;91(11):821-4.
7
Biology of myasthenia gravis.重症肌无力的生物学
Annu Rev Pharmacol Toxicol. 1980;20:337-62. doi: 10.1146/annurev.pa.20.040180.002005.
8
[Current therapeutic aspects of myasthenia gravis].[重症肌无力的当前治疗方面]
Rev Clin Esp. 1981 Oct 31;163(2):139-44.
9
Scientific overview of myasthenia gravis and an assessment of the role of plasmapheresis.重症肌无力的科学概述及血浆置换作用评估
Prog Clin Biol Res. 1982;106:113-42.
10
[Pathogenesis, diagnosis, and treatment of myasthenia (review of the foreign literature)].重症肌无力的发病机制、诊断与治疗（国外文献综述）
Zh Nevropatol Psikhiatr Im S S Korsakova. 1980;80(11):1729-34.
引用本文的文献
1
Clinical and electromyographic characteristics of pathological muscular-fatigue syndromes of the myasthenia type.肌无力型病理性肌肉疲劳综合征的临床及肌电图特征
Neurosci Behav Physiol. 1984 Jul-Aug;14(4):261-7. doi: 10.1007/BF01149608.
本文引用的文献
1
IMMUNOLOGICAL DISTURBANCES IN MYASTHENIA GRAVIS WITH A REPORT OF HASHIMOTO'S DISEASE DEVELOPING AFTER THYMECTOMY.重症肌无力的免疫紊乱及胸腺切除术后发生桥本甲状腺炎的病例报告
J Neurol Neurosurg Psychiatry. 1964 Dec;27(6):485-92. doi: 10.1136/jnnp.27.6.485.
2
AN ELECTROPHYSIOLOGICAL INVESTIGATION OF NEUROMUSCULAR TRANSMISSION IN MYASTHENIA GRAVIS.重症肌无力神经肌肉传递的电生理研究
J Physiol. 1964 Nov;174(3):417-34. doi: 10.1113/jphysiol.1964.sp007495.
3
Search for a neuromuscular blocking agent in the blood of patients with myasthenia gravis.在重症肌无力患者的血液中寻找神经肌肉阻滞剂。
Am J Med. 1959 Mar;26(3):394-409. doi: 10.1016/0002-9343(59)90248-7.
4
Myasthenia gravis: evaluation of treatment in 1,355 patients.重症肌无力：1355例患者的治疗评估
Neurology. 1966 May;16(5):431-9. doi: 10.1212/wnl.16.5.431.
5
Myasthenia gravis as an autoimmune disease: clinical aspects.重症肌无力作为一种自身免疫性疾病：临床方面。
Ann N Y Acad Sci. 1966 Jan 26;135(1):506-16. doi: 10.1111/j.1749-6632.1966.tb45499.x.
6
Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment.重症肌无力中逐渐增加泼尼松剂量。降低治疗风险。
N Engl J Med. 1974 Jan 10;290(2):81-4. doi: 10.1056/NEJM197401102900204.
7
Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors.重症肌无力中的神经肌肉接头：乙酰胆碱受体减少。
Science. 1973 Oct 19;182(4109):293-5. doi: 10.1126/science.182.4109.293.
8
Autoimmune response to acetylcholine receptor.对乙酰胆碱受体的自身免疫反应。
Science. 1973 May 25;180(4088):871-2. doi: 10.1126/science.180.4088.871.
9
Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors.重症肌无力中的血清球蛋白：对α-银环蛇毒素与乙酰胆碱受体结合的抑制作用
Science. 1974 Oct 4;186(4158):55-7. doi: 10.1126/science.186.4158.55.
10
Corticosteroids in management of severe, generalized myasthenia gravis. Effectiveness and comparison with corticotropin therapy.
Neurology. 1972 Jun;22(6):603-10. doi: 10.1212/wnl.22.6.603.
Zotero 插件